Ravagnan G, Piccolomini R, Speciale A M, Russo G, Renzini G
Chemotherapy. 1985;31(3):191-9. doi: 10.1159/000238335.
The antimicrobial activities of nalidixic acid-cephalexin (ratio 1:1) and cinoxacin-cefadroxil (ratio 1:2) combinations have been evaluated against 396 clinical isolates; many of them were nalidixic acid- or cinoxacin-resistant organisms (MIC greater than or equal to 100 micrograms/ml). We have also tested the nalidixic acid-amoxicillin combination (ratio 1:1) against 225 amoxicillin-resistant bacterial strains (MIC greater than or equal to 800 micrograms/ml). Synergy was found for 62-70% of the Enterobacteriaceae and nonfermenter bacilli tested and for 85-92% of the gram-positive bacterial strains. The 225 clinical isolates resistant to amoxicillin (MIC greater than or equal to 800 micrograms/ml) were synergistically inhibited by the nalidixic acid-amoxicillin combination.
已对萘啶酸-头孢氨苄（比例1:1）和西诺沙星-头孢羟氨苄（比例1:2）组合针对396株临床分离株的抗菌活性进行了评估；其中许多是对萘啶酸或西诺沙星耐药的菌株（最低抑菌浓度大于或等于100微克/毫升）。我们还对萘啶酸-阿莫西林组合（比例1:1）针对225株对阿莫西林耐药的细菌菌株（最低抑菌浓度大于或等于800微克/毫升）进行了测试。在所测试的肠杆菌科和非发酵菌中，62% - 70%以及在革兰氏阳性菌中85% - 92%发现有协同作用。对阿莫西林耐药（最低抑菌浓度大于或等于800微克/毫升）的225株临床分离株被萘啶酸-阿莫西林组合协同抑制。
